Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | UBE2N | P61088 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 9/20 | 0.35 |
| ▸ | PPME1 | Q9Y570 | 2/20 | 0.33 |
| ▸ | APEH | P13798 | 1/20 | 0.33 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31578890 | 0.89 | PTGDR (0.37) | PTGDRPTGDR2SRCBRD4HTR6 | |
| SCHEMBL31579010 | 0.83 | PTGDR (0.39) | PTGDRPTGDR2SRCBRD4HTR6 | |
| SCHEMBL25423168 | 0.79 | SRC (0.41) | PTGDRPTGDR2SRCBRD4HTR6 | |
| SCHEMBL25420154 | 0.73 | MTNR1B (0.54) | SRCHTR6 | |
| SCHEMBL25424320 | 0.73 | HTR6 (0.39) | PTGDRPTGDR2SRCHTR6 | |
| SCHEMBL30405736 | 0.73 | HTR6 (0.39) | PTGDRPTGDR2SRCHTR6 | |
| SCHEMBL25811440 | 0.71 | PTGDR2 (0.46) | KDM4EUBE2NPTGDRPTGDR2SRC | |
| SCHEMBL25421448 | 0.71 | CA12 (0.51) | SRCHTR6CXCL8NOD1PPARG | |
| SCHEMBL2131849 | 0.70 | KDM4E (0.47) | KDM4EUBE2NPTGDRPTGDR2SRC | |
| SCHEMBL30406055 | 0.70 | ALDH1A1 (0.42) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022120-A1 | Inhibitors of MENIN-MLL Interaction | BALA THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | KDM4E 136/4885UBE2N 1614/4885PTGDR 4314/4885 |
| US-20260022120-A1 | Inhibitors of MENIN-MLL Interaction | MEN1, MLLT1, MLLT3 | KDM4E 75/4885UBE2N 1052/4885PTGDR 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.